| |
3003 ApoE ε4 carrier study
|
3002 ApoE ε4 noncarrier study
|
|---|
|
PBO + BAP 0.5 (n = 215)
|
BAP 0.5 + BAP 0.5 (n = 275)
|
PBO + BAP 0.5 (n = 39)
|
PBO + BAP 1.0 (n = 37)
|
BAP 0.5 + BAP 0.5 (n = 66)
|
BAP 1.0 + BAP 1.0 (n = 56)
|
|---|
|
Mean age (years)
|
71.4
|
72.1
|
68.7
|
68.9
|
71.4
|
70.6
|
|
Femalea (%)
|
62.8
|
67.6
|
64.1
|
59.5
|
53.0
|
62.5
|
|
Whitea (%)
|
79.5
|
75.6
|
76.9
|
81.1
|
74.2
|
66.1
|
|
Asian (%)
|
18.1
|
22.9
|
23.1
|
18.9
|
25.8
|
32.1
|
|
Mean duration of AD (years)
|
4.49
|
4.58
|
4.16
|
4.50
|
4.44
|
4.46
|
|
Mean baseline MMSE
|
19.0b
|
19.2
|
18.6c
|
17.1
|
19.1
|
18.4
|
|
Current AChEI and/or memantine use, n (%)
|
|
Yes
|
193 (89.8)
|
242 (88.0)
|
34 (87.2)
|
31 (83.8)
|
51 (77.3)
|
53 (94.6)
|
|
No
|
22 (10.2)
|
33 (12.0)
|
5 (12.8)
|
6 (16.2)
|
15 (22.7)
|
3 (5.4)
|
-
AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, ApoE apolipoprotein E, BAP bapineuzumab, MMSE Mini-Mental State Examination, PBO placebo
-
aA few patients may have been misclassified at baseline, causing discrepancy with Table 2: one patient was classified as male at parent baseline and female at extension baseline; three patients were classified as white at parent baseline and Asian or “other” at extension baseline
-
b
n = 212
-
c
n = 38
